Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Nevada: - OptumCare Nevada — Las Vegas, Nevada
- Local Institution - 007-938A — Las Vegas, Nevada
- Local Institution - 007-938B — Las Vegas, Nevada
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Nevada: - Research Site — Las Vegas, Nevada
- Research Site — Reno, Nevada
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Nevada: - Research Site — Las Vegas, Nevada
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Nevada: - OptumCare Cancer Care — Las Vegas, Nevada
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Nevada: - OptumCare Cancer Care at Charleston — Las Vegas, Nevada
- OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT06568939
Sites in Nevada: - Renown Regional Medical Center /ID# 273535 — Reno, Nevada
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Nevada: - Research Site 110 — Las Vegas, Nevada
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutat…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT05967689
Sites in Nevada: - Comprehensive Cancer Centers of Nevada - Central Valley - Twain — Las Vegas, Nevada
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all …
Sponsor: Chipscreen Biosciences, Ltd.
NCT ID: NCT05271292
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Las Vegas Cancer Center-Henderson — Henderson, Nevada
Recruiting Industry
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-c…
Sponsor: Freenome Holdings Inc.
NCT ID: NCT06122077
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada